Under a tenth of patients who could benefit from obesity jabs including Wegovy are able to get them, caution the WHO as it releases its initial advice on the medications.
Considering in excess of 1,000,000,000 individuals worldwide now classified as obese, it is calling for broader and more equitable access to these injectable treatments.
According to projections, over two billion are projected to be living with obesity by 2030 unless action is taken.
"Our new guidelines acknowledges that obesity is a chronic disease that can be addressed with thorough and ongoing support," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and supply-chain constraints are major hurdles to universal availability to the treatments that can help people shift considerable weight, explains the organization.
Skinny Jab Scarcity
Even in the current best projected outlook, the production of GLP-1 therapies could only cover about 100 million people – under 10% of the global need, per the WHO.
The guideline encourages nations and manufacturers to expand availability, through measures like licensing agreements.
A patent on the active ingredient – the primary component of a leading brand – is scheduled to end in a number of countries in 2026.
How Weight-Loss Drugs Work
GLP-1 drugs imitate a body's own hormone to slow digestion, curb appetite and enhance the sense of being full so individuals reduce food intake.
Individuals commonly begin shedding pounds within a few weeks of beginning the once-weekly jabs.
Research points to people may put most of the weight back on a year later of halting the treatment, because their normal food cravings resume.
To be carrying excess weight increases your likelihood for contracting health problems, like diabetes, cardiovascular issues, brain attack, and some cancers.
Excess weight concerns individuals in every country and was linked to over three and a half million fatalities worldwide in 2024, according to the WHO.
